Ascent Strategic Communications

Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026

- FDA confirmed the resubmission is a complete, Class II response to the Aug. 27, 2025 CRL.

28 July 2026

New Housing Law Could Open Doors for Homebuyers and Individual Real Estate Investors

Global Real Estate Veteran Angela Healy says increasing housing supply remains critical to affordability and workforce growth

28 July 2026

OMSA Calls on Congress to End Regulatory Disparities Hurting U.S.-Flagged Vessels

Restated Marine Safety Mission and New Civilian Secretary of the Coast Guard proposed as solutions

23 July 2026

BrightDot Founder and CEO Bill Crouch Releases New Book: “Mattership™: Making Donors Feel They Matter”

New book reframes fundraising as relationship-building, not transaction-chasing

20 July 2026

Statement from James Dismond, CEO of MiraSol Health on CMS’ Proposed Palliative Care Policy

BLUFFTON, S.C., July 20, 2026 -- "The Centers for Medicare & Medicaid Services’s proposal to recognize community-based palliative care under the Medicare home health benefit is one of the most significant federal policy developments we've seen for serious illness car...

20 July 2026

OMSA: American Jobs Are Paying for a Jones Act Waiver That Hasn't Worked

NEW ORLEANS -- The Offshore Marine Service Association (OMSA) is responding to reports that the Trump administration is considering extending the current Jones Act waiver, warning that another extension would only further undermine the American maritime industry while co...

17 July 2026

Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines

- Investment secures runway to reach cash flow positivity -

Atrium Health and OrthoCarolina join forces to build nationally recognized orthopedic destination

Expanded collaboration builds on a longstanding relationship to advance access, coordinated care, education and innovation

13 July 2026

Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome

– Comprehensive updates to be presented at Barth Syndrome Foundation conference –

8 July 2026

Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease

Existing data supports direct path to resubmission following constructive FDA engagement